Methods of Identifying Agents Having Antiangiogenic Activity
OwnerMarsha Rosner, Wei-Jen Tang +1inventors
InventorsMarsha Rosner, Wei-Jen Tang, Jia Hong
Life of this patent
Estimating the term…
Abstract
Provided are assays and methods of identifying antiangiogenic agents including contacting an endothelial cell with a putative antiangiogenic agent and assaying for activation of Rap-1 in the endothelial cell. Also provided are methods of inhibiting angiogenesis and treating conditions associated with improper angiogenesis. Compositions comprising activators of Rap-1 and methods of activating the Rap-1 signaling pathway are also provided. Methods of inhibiting chemotaxis and angiogenesis by contacting cells with Rho inhibitors are provided.
Claims38
A method of testing an agent for antiangiogenic activity comprising contacting an endothelial cell with the agent and assaying for activation of Rap-1 in the endothelial cell, activation of Rap-1 in the endothelial cell being indicative of antiangiogenic activity.
A method of inhibiting angiogenesis in a cell population comprising contacting one or more of the cells in the population with an agent that activates Rap-1 or the Rap-1 signaling pathway.
A method of treating a condition characterized by ocular neovascularization in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent that activates Rap-1.
An pharmaceutical composition comprising a Rap-1 activator.
A method of inhibiting angiogenesis in a cell population comprising delivering to at least one cell of the cell population a polynucleotide encoding a constitutively active Rap-1 polypeptide, the polynucleotide operably connected to a promoter functional in the at least one cell to obtain expression of the Rap-1 polypeptide at a level sufficient to inhibit angiogenesis.
A kit for inhibiting angiogenesis comprising a polynucleotide encoding a constitutively active Rap-1 polypeptide.
A method of inhibiting chemotaxis in a cell comprising contacting one or more cells with an agent that inhibits Rho kinase.
Dependencies are inferred from the claim text.